



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

REFERENCES:

Background

1. Diabetes Canada. 2018 Clinical Practice Guidelines. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. *Can J Diabetes* 2018;42:S88-S103.
2. American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Pharmacologic Approaches to Glycemic Treatment. *Diabetes Care* 2019;42:S90-S102.
3. Palmer S, Mavridis D, Micoloucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta analysis. *JAMA* 2016;316:313-324.
4. Canadian Agency for Drugs and Technologies in Health. Third-line pharmacotherapy for type 2 diabetes-Update. Ottawa: The Agency; 2013 (CADTH optimal use report; vol.3, no.1b). [Internet]. https://www.cadth.ca/sites/default/files/pdf/OP0512_Diabetes%20Update_Third-line_e.pdf
5. Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Acute Care Settings. [Internet]. <https://www.ismp.org/sites/default/files/attachments/2018-08/highAlert2018-Acute-Final.pdf>
6. Institute for Safe Medication Practices. ISMP List of High-Alert Medications in Community/Ambulatory Healthcare. [Internet]. <https://www.ismp.org/sites/default/files/attachments/2017-11/highAlert-community.pdf>
7. Institute for Safe Medication Practices Canada. Insulin Medication Incidents in the Community. [Internet]. <https://www.ismp-canada.org/download/PharmacyConnection/PC2016-InsulinMedicationIncidentsintheCommunity.pdf>
8. Institute for Safe Medication Practices Canada. Prevention medication errors with new high-concentration insulins. [Internet]. https://www.ismp-canada.org/download/safetyBulletins/2015/ISMPCSB2015-10_TALLman.pdf
9. Prescrire. High-strength insulins: think and act in units to prevent errors. *Prescrire International* 2019;28:70-71.
10. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Lantus insulin glargine recombinant. NDA 021081. 2000. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus_medr.pdf
11. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Levemir insulin detemir recombinant. NDA 021536. 2005. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_Levemir_medr.PDF
12. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Tresiba insulin degludec. NDA 203314. 2015. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313Orig1s000_203314Orig1s000MedR.pdf
13. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Basaglar insulin glargine. NDA 205692. 2015. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000MedR.pdf
14. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Toujeo Solostar insulin glargine recombinant. NDA 206538. 2015. Medical Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000MedR.pdf



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

Evidence for Practice: Hypoglycemia Risk Differences for Basal Insulins

1. Canadian Agency for Drugs and Technologies in Health. Optimal Therapy Report. COMPUS. Long-acting Insulin Analogues for the Treatment of Diabetes Mellitus: Meta-analyses of Clinical Outcomes – Update of CADTH Technology Report No. 92. [Internet].
https://cadth.ca/sites/default/files/pdf/compus_Long-Acting-Insulin-Analogs-Report_Clinical-Outcomes.pdf
2. Singh S, Ahman F, Lal A, et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta analysis. *CMAJ* 2009;180(4):385-97.
3. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2007, Issue 2. Art. No. CD005613.
4. Madenidou A, Paschos P, Karagiannis T, et al. Comparative Benefits and Harms of Basal Insulin Analogues for Type 2 Diabetes. *Ann Intern Med* 2018;169:165-174.
5. Engler J, Horvath K, Semlitsch T, et al. Long-acting insulin analogues versus human insulin for type 2 diabetes mellitus: update of a Cochrane review. ePoster #834. 2019 European Association for the Study of Diabetes. ePoster #834. [Internet].
<https://www.easd.org/virtualmeeting/home.html#!resources/long-acting-insulin-analogues-versus-human-isophane-insulin-for-type-2-diabetes-update-of-a-cochrane-review-9ba3d6f7-1094-4096-aca3-6a52fb15fa2a>
6. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Lantus insulin glargine recombinant. NDA 021081. 2000. Medical Review. [Internet].
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus_medr.pdf
7. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Levemir insulin detemir recombinant. NDA 021536. 2005. Medical Review. [Internet].
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021-536_Levemir_medr.PDF
8. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Tresiba insulin degludec. NDA 203314. 2015. Medical Review. [Internet].
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/203313Orig1s000_203314Orig1s000MedR.pdf
9. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Basaglar insulin glargine. NDA 205692. 2015. Medical Review. [Internet].
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205692Orig1s000MedR.pdf
10. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Toujeo Solostar insulin glargine recombinant. NDA 206538. 2015. Medical Review. [Internet].
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000MedR.pdf
11. Holleman F, Gale E. Nice insulins, pity about the evidence. *Diabetologia* 2007;50:1783-90
12. Balijepalli C, Druyts E, Siliman G, et al. Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes. *Clin Epidemiol* 2017;9:291-296.
13. Frier B, Ratzki-Leewing A, Harris S. Reporting of hypoglycemia definitions in clinical trials of basal insulins: a need for consensus. *Diabetes Obes Med* 2019 March 29 [Epub ahead of print].
14. Swinnen S, Mullins P, Miller Me, et al. Changing the cut-off values that define hypoglycemia has a major effect on reported frequencies of hypoglycemia. *Diabetologia* 2009;52:38-41.
15. Swinnen S, Simon A, Holleman F, et al. Insulin detemir versus insulin glargine for type 2 diabetes mellitus (Review). *Cochrane Database Syst Rev* 2011, Issue 7. Art. No. CD006383.
16. Health Canada. Product Monograph. Tresiba insulin degludec injection. [Internet].
https://pdf.hres.ca/dpd_pm/00046475.PDF



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

17. Marso S, McGuire D, Zinman B, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *N Engl J Med* 2017;377:723-732.
18. U.S. National Library of Medicine. ClinicalTrials.gov. A Trial Comparing Cardiovascular Safety of Insulin Degludec versus Insulin Glargine in Subjects with Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE). <https://clinicaltrials.gov/ct2/show/NCT01959529>.
19. American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Pharmacologic Approaches to Glycemic Treatment. *Diabetes Care* 2019;42:S90-S102.
20. Wexler D. Insulin therapy in type 2 diabetes mellitus. UpToDate. [Internet]. <https://www.uptodate.com/contents/insulin-therapy-in-type-2-diabetes-mellitus>
21. Lipska K, Parker M, Moffet H, et al. Association of initiation of basal insulin analogs vs neutral protamine Hagedorn insulin with hypoglycemia-related emergency department visits of hospital admissions and with glycemic control in patients with type 2 diabetes. *JAMA* 2018;320:53-62.

Table 1: Guideline Recommendations – Glycemic Targets for Type 2 Diabetes

1. Diabetes Canada. 2018 Clinical Practice Guidelines. Targets for Glycemic Control. *Can J Diabetes* 2018;42:S42-S46.
2. Qaseem A, Wilt TJ, Kansagara D, et al. Hemoglobin A1c Targets for Glycemic Control With Pharmacologic Therapy for Nonpregnant Adults With Type 2 Diabetes Mellitus: A Guidance Statement Update From the American College of Physicians. *Ann Intern Med*. 2018 Apr 17;168(8):569-576. Epub 2018 Mar 6.
3. Diabetes Canada. 2018 Clinical Practice Guideline. Diabetes in Older People. *Can J Diabetes* 2018;42:S283-S295

Table 2: Clinical Considerations of Basal Insulins for Type 2 Diabetes

1. Lipska K, Hirsch I. Human Insulin for Type 2 Diabetes An Effective, Less-Expensive Option. *JAMA* 2017;318(1):23-24.
2. Health Canada. Product Monograph. Humulin N insulin isophane, human biosynthetic injection. [Internet]. https://pdf.hres.ca/dpd_pm/00034827.PDF
3. Health Canada. Product Monograph. Novolin ge NPH insulin isophane, human biosynthetic. [Internet]. https://pdf.hres.ca/dpd_pm/00034033.PDF
4. Health Canada. Product Monograph. Lantus insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00041813.PDF
5. Health Canada. Product Monograph. Basaglar insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00038146.PDF
6. Health Canada. Summary Basis of Decision for Basaglar. [Internet]. <https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00281>
7. Health Canada. Fact Sheet: Biosimilars. [Internet]. <https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/fact-sheet-biosimilars.html>
8. Health Canada. Product Monograph. Toujeo SoloSTAR insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00046228.PDF
9. U.S. Food and Drug Administration Prescribing Information. Toujeo SoloSTAR insulin glargine recombinant. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf
10. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Toujeo SoloSTAR insulin glargine recombinant. NDA 206538. 2015. Pharmacology Review. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206538Orig1s000PharmR.pdf



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

11. Health Canada. Product Monograph. Levemir insulin detemir injection. [Internet]. https://pdf.hres.ca/dpd_pm/00042063.PDF
12. Health Canada. Product Monograph. Tresiba insulin degludec injection. [Internet]. https://pdf.hres.ca/dpd_pm/00046475.PDF
13. U.S. Food and Drug Administration. Prescribing Information. Tresiba insulin degludec injection. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203314s010lbl.pdf
14. Swinnen G, Holleman F, DeVries J. The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back. *Diabetologia* 2008;51:1790–1795.
15. Diabetes Canada. 2018 Clinical Practice Guidelines. Appendix 9. Examples of Insulin Initiation and Titration Regimens in People with Type 2 Diabetes. *Can J Diabetes* 2018;42:S317-318
16. Diabetes Canada. 2018 Clinical Practice Guidelines. Insulin Prescription Tool. [Internet]. <http://guidelines.diabetes.ca/reduce-complications/insulin-prescription-tool>

Cost of Basal Insulins

1. McKesson Canada [Internet]. <https://www.mckesson.ca/> (Accessed May 21, 2019)

Risk Factors for Hypoglycemia

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Pharmacologic Approaches to Glycemic Treatment. *Diabetes Care* 2019;42:S90-S102.
2. Diabetes Canada. 2018 Clinical Practice Guidelines. Hypoglycemia. *Can J Diabetes* 2018;42:S104-S108.
3. U.S. Department of Veterans Affairs. Hypoglycemia Safety Initiative. [Internet]. https://www.qualityandsafety.va.gov/ChoosingWiselyHealthSafetyInitiative/HypoglycemiaSite/For_Clinicians.asp

Table 3: Initiation and Titration of Basal Insulin based on Fasting Glucose Goals

1. Diabetes Canada. 2018 Clinical Practice Guidelines. Targets for Glycemic Control. *Can J Diabetes* 2018;42:S42-S46.
2. American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Pharmacologic Approaches to Glycemic Treatment. *Diabetes Care* 2019;42:S90-S102.
3. Lipska K, Hirsch I. Human Insulin for Type 2 Diabetes An Effective, Less-Expensive Option. *JAMA* 2017;318(1):23-24.
4. U.S. Food and Drug Administration Prescribing Information. Toujeo SoloSTAR insulin glargine recombinant. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/206538lbl.pdf
5. U.S. Food and Drug Administration. Prescribing Information. Tresiba insulin degludec injection. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/203314s010lbl.pdf
6. Health Canada. Safety Alert: New restrictions on the use of rosiglitazone products due to cardiac safety concerns (Avandia, Avandamet, Avandaryl) For Health Professionals. 2007. [Internet]. <http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2007/14441a-eng.php>
7. Health Canada. Safety Alert: SGLT2 Inhibitors [INVOKANA (canagliflozin), FORXIGA (dapagliflozin), XIGDUO (dapagliflozin/metformin), JARDIANCE (empagliflozin)] - Risk of Diabetic Ketoacidosis. 2016. [Internet]. <http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2016/58404a-eng.php>



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

8. U.S. Food and Drug Administration Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. [Internet]. <https://www.fda.gov/downloads/Drugs/DrugSafety/UCM475487.pdf>
9. European Medicines Agency. EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes. [Internet]. <https://www.ema.europa.eu/en/news/ema-confirms-recommendations-minimise-ketoacidosis-risk-sglt2-inhibitors-diabetes>

Switching Basal Insulins in Type 2 Diabetes

1. Institute for Safe Medication Practices Canada. Insulin Medication Incidents in the Community. [Internet]. <https://www.ismp-canada.org/download/PharmacyConnection/PC2016-InsulinMedicationIncidentsintheCommunity.pdf>
2. Health Canada. Product Monograph. Basaglar insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00038146.PDF
3. Health Canada. Product Monograph. Lantus insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00041813.PDF
4. U.S. Food and Drug Administration Prescribing Information. Levemir insulin detemir. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021536s054lbl.pdf
5. Health Canada. Product Monograph. Tresiba insulin degludec injection. [Internet]. https://pdf.hres.ca/dpd_pm/00046475.PDF
6. Health Canada. Product Monograph. Toujeo SoloSTAR insulin glargine injection. [Internet]. https://pdf.hres.ca/dpd_pm/00046228.PDF
7. Anderson SL, Trujillo JM, Anderson JE, Tanenberg RJ. Switching basal insulins in type 2 diabetes: practical recommendations for health care providers. *Postgraduate Medicine*. 2017. DOI: 10.1080/00325481.2018.1419048
8. Kocurek B, Cryar K. Information for Health Care Professionals Switching between Insulin Products in Disaster Response Situations. August 2018 [Internet]. <http://www.diabetes.org/assets/pdfs/living/emergency-preparedness/switching-between-insulin-1.pdf>
9. Lipska K, Hirsch I. Human Insulin for Type 2 Diabetes An Effective, Less-Expensive Option. *JAMA* 2017;318(1):23-24.
10. Prescrire. High-strength insulins: think and act in units to prevent errors. *Prescrire International* 2019;28:70-71.

Evidence to Practice

1. Lipska K, Ross J, Miao Y, et al. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. *JAMA Int Med* 2015;175:356-362.
2. McAlister F, Youngson E, Eurich D. Treatment deintensification is uncommon in adults with type 2 diabetes mellitus. A retrospective cohort study. *Circ Cardiovasc Qual Outcomes* 2017;10:e003514
3. Arnold S, Lipska K, Wang Jingyan. Use of intensive glycemic management in older adults with diabetes mellitus. *J Am Geriatr Soc* 2018;66:1190-1194.
4. American Diabetes Association. Standards of Medical Care in Diabetes - 2019. Older Adults. *Diabetes Care* 2019;42:S139-S147.
5. Choosing Wisely Canada Geriatrics. [Internet]. <https://choosingwiselycanada.org/geriatrics/>



Basal Insulins for Type 2 Diabetes: How Does Insulin Choice Affect the Risk of Hypoglycemia and Medication Cost?

B.C. Provincial Academic Detailing Service

May 31, 2019

6. U.S. Department of Veterans Affairs. Hypoglycemia Safety Initiative. [Internet]. https://www.qualityandsafety.va.gov/ChoosingWiselyHealthSafetyInitiative/HypoglycemiaSite/For_Clinicians.asp
7. Institute for Safe Medication Practices. ISMP Guidelines for Optimizing Safe Subcutaneous Insulin Use in Adults. [Internet]. <https://www.ismp.org/sites/default/files/attachments/2018-09/ISMP138D-Insulin%20Guideline-090718.pdf>
8. Institute for Safe Medication Practices Canada. Insulin Medication Incidents in the Community. [Internet]. <https://www.ismp-canada.org/download/PharmacyConnection/PC2016-InsulinMedicationIncidentsintheCommunity.pdf>